500 mn Covid vaccine doses to be made available by Aug: Harsh Vardhan

India's coronavirus caseload mounted to 89,58,483 on Thursday with 45,576 infections being reported in a day, while the death toll climbed to 1,31,578 with 585 new fatalities

Coronavirus, vaccine, covid, drugs, clinical trials — Health Minister Harsh Vardhan on Thursday said health care workers and people aged above 65 would be early recipients when a vaccine becomes available

2 min read Last Updated : Nov 19 2020 | 11:40 PM IST

Noting that it is natural to prioritise Covid-19 vaccine distribution, Health Minister Harsh Vardhan on Thursday said health care workers and people aged above 65 would be early recipients when a vaccine becomes available. Addressing a webinar organised by the FICCI FLO on ‘The Shifting Healthcare Paradigm During and Post-Covid', he said Covid-19 vaccine will be available in next few months and it is estimated that by July-August 400-500 million doses will be made available for 25-30 crore people.

“The vaccine distribution would have to be prioritised. As you know the health care workers who are corona warriors they will be prioritised, then people who are above 65 years of age they have been prioritised, then those from 50-65 years of age have been prioritised,” he said.

“Then those below 50 years who have other diseases. It is all being decided by experts with a scientific point of view. We have made a very detailed, meticulous plan on this. What we would have to do in March-April next year, we have started planning for it from now only,” Vardhan said.

India's coronavirus caseload mounted to 89,58,483 on Thursday with 45,576 infections being reported in a day, while the death toll climbed to 1,31,578 with 585 new fatalities.

The phase-3 trial of the Oxford vaccine of the Serum Institute is almost near completion, while the phase-3 clinical trial of the indigenously-developed vaccine candidate of the Bharat Biotech and the Indian Council of Medical Research (ICMR) has already started.

Dr Reddy’s will soon start the combined phase-2 and phase-3 clinical trials of the Russian Covid-19 vaccine, Sputnik V, in India. Also, the Biological E Limited has started early phases 1 and 2 human trials of its Covid-19 vaccine candidate. Pfizer and BioNTech SE said their vaccine candidate was found to be more than 95 per cent effective in preventing Covid-19, while Moderna has said its vaccine candidate against Covid-19 found it to have an efficacy of 94.5 per cent.